TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04590339

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided inferior Alveolar Nerve lateralization
Description: Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Guided inferior Alveolar Nerve lateralization
Description: Evaluating neurosensory recovery after Implant placement in posterior atrophic mandible by Guided inferior alveolar nerve lateralization technique
Study: NCT01833754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered as three 70 mg/mL prefilled syringe injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered as three 70 mg/mL prefilled syringe injections
Study: NCT04228172

Intervention type: OTHER
Intervention: Clinical and neuropsychological assessments
Description: Investigator will evaluate subjects according to the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), the standard clinical tool used to measure the severity and progression of PD. Neuropsychological evaluation will assess how one's brain functions (via pencil and paper testing), which indirectly yields information about the structural and functional integrity of the brain. Conducted at baseline and 18 months later.
Study: NCT03086421

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
Study: NCT01250288

Intervention type: OTHER
Intervention: Personal Health Management System
Description: BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients \& their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.

Intervention type: OTHER
Intervention: Personal Health Management System
Description: BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients \& their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
Study: NCT02294773

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination
Description: Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination
Description: Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Patient is to take clomiphene citrate during cycle days 3-7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Patient is to take clomiphene citrate during cycle days 3-7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Patient is to take letrozole during cycle days 3-7.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Patient is to take letrozole during cycle days 3-7.
Study: NCT02723877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQR309
Description: Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: non.taxane microtubule dynamics inhibitor
Study: NCT03464552

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Colposcopic guided biopsy
Description: Patient is placed in the lithotomy position. Vulva is examined for any suspicious lesions. A sterile bivalve speculum is introduced into the vagina to inspect cervix. A 3% acetic acid solution is applied to the cervix to map acetowhite areas for colposcopic directed punch biopsy using Tischler punch forceps.
Study: NCT01865084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02857361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual ketamine wafers
Description: Two sublingual ketamine 25 mg wafers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual ketamine wafers
Description: Two sublingual ketamine 25 mg wafers
Study: NCT03887403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention
Study: NCT03464552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: oral capsule 3 hours before procedure
Study: NCT03887403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study: NCT00953550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium-Sugammadex
Description: Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Succinylcholine
Description: 1 mg/kg
Study: NCT01833754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered as three 70 mg/mL prefilled syringe injections
Study: NCT00376740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: zoledronic acid
Description: Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
Study: NCT03990766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline delivered via high-volume, low-pressure nasal saline irrigation
Study: NCT00096954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab (Xolair)
Description: Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of \> 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
Study: NCT03698552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADCT-602
Description: Starting dose of ADCT-602: 30 μg/kg given by vein.
Study: NCT04274478

Intervention type: DEVICE
Group type: OTHER
Intervention: Auditive cueing
Description: Based on gait measurement, auditive cueing is generated automatically to check its impact on patients with Freezing Of Gait.
Study: NCT03990766

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal
Description: Lactose delivered via high-volume, low-pressure nasal saline irrigation
Study: NCT02060201

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin
Study: NCT06332248

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: The dietary supplement magnesium (375 mg) was given daily for up to 3 months (oral intake).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, oral intake once a day for up to three months.
Study: NCT00964132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX194204
Description: Once Daily, Oral
Study: NCT01607268

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopy Imaging
Description: Proton magnetic resonance spectroscopy \[1H-MRS\] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Spectroscopy Imaging
Description: Proton magnetic resonance spectroscopy \[1H-MRS\] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
Study: NCT03973073

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CapulinTM
Description: camouflage

Intervention type: OTHER
Group type: OTHER
Intervention: topical applications and NB-UVB
Description: combination therapy of vitiligo
Study: NCT00126113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPT-based Counseling
Description: Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Educational Counseling
Description: Standard educational counseling consisting of explanation of hearing tests
Study: NCT02060201

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin/Dapagliflozin FDC

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin/Dapagliflozin FDC

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin/Dapagliflozin FDC

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin/Dapagliflozin FDC
Study: NCT02949765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sulfate 105 mg
Description: Daily supplementation with iron sulfate 105 mg 1 pill/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron-rich diet
Study: NCT02464787

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LifePak Nano
Description: Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
Study: NCT01452776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
Study: NCT00376740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
Study: NCT00499824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education of general practitioners on the IDF-WPR guidelines
Description: The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:~an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient.
Study: NCT01557751

Intervention type: GENETIC
Group type: OTHER
Intervention: Whole blood for genotyping
Description: This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
Study: NCT04681586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bright light therapy
Description: using a bright light therapy device (10.000 lux) for 30min every morning for two weeks

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dim red light
Description: using the same device as the active group, but with an installed filter that dims light to \<300 lux for 30min every morning for two weeks
Study: NCT01016340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MCS
Description: MCS-5 Softgel 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MCS
Description: MCS-5 Softgel 5 mg
Study: NCT00055809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-interferon alfa-2b
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT05167617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vit D
Description: Vit D was provided as 2000 IU daily for 3 and 6 months for patients who had mild and moderate HVD, respectively.
Study: NCT02629016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wellness
Study: NCT03936894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab Injection [Ilaris]
Description: Subject receives subcutaneous injection of canakinumab 2 mg/ kg or 4 mg/kg
Study: NCT00462839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: blood loss estimation
Description: Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blood loss estimation
Description: Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
Study: NCT01507233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine sulfate
Description: Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL (bupivacaine liposome injectable suspension)
Description: Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed.
Study: NCT02185963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg once a daily for 12 weeks
Study: NCT03017352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT02874950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: office exercise training
Description: The exercise group, did 6 months office exercise training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ergonomic modification
Description: The ergonomic modification group, followed 6 months modified office ergonomic modification.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and ergonomic
Description: The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group did not do any exercise and did not follow any ergonomic modification.
Study: NCT00050076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-135
Description: MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-135
Description: MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCC-135
Description: MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
Study: NCT06535711

Intervention type: RADIATION
Intervention: Acute CT
Description: Acute CT (a CT within 24 h)

Intervention type: RADIATION
Intervention: Deferred CT
Description: Deferred CT (a CT within 3-4 weeks)
Study: NCT02224053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZD9291
Description: Blood sampling to measure AZD9291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291 tablet dosing
Description: AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole tablet dosing
Description: Omeprzole taken from Days 1 to 5 in Period 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling - AZ5140 and AZ7550
Description: Blood samples to measure levels of AZ5140 and AZ7550
Study: NCT01452776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
Study: NCT05768620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAVE
Description: The training is designed to train spatial navigation and memory and in particular egocentric and allocentric processes
Study: NCT03973073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical applications and NB-UVB
Description: combination therapy of vitiligo
Study: NCT03311620

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)
Description: Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
Study: NCT01037322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cannabidiol
Description: cannabidiol given in olive oil drops, 5 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo in drops
Description: olive oil containing no drug given in drops twice daily
Study: NCT02469207

Intervention type: OTHER
Intervention: Removal of tissue post-mortem
Study: NCT03511118

Intervention type: DRUG
Intervention: Tranexamic acid (TXA)
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: labetalol
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: metformin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: nifedipine
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.

Intervention type: DRUG
Intervention: clindamycin
Description: Understudied drugs will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider.